• ISIRGAPOVA Sarvinoz Narzullayevna
  • SULTONOV Nodir Nazirovich


CKD, climacteric period, replacement therapy, scheduled hemodialysis, quality of life


Nowadays, there is a tendency to increase the life expectancy of the population all over the world. This depends in many respects on the improvement of diagnosis and treatment of chronic diseases: primarily heart, bronchus and lungs, as well as kidney diseases. At the same time, even at an advanced stage of functional organ failure, modern methods of conservative therapy allow such patients to maintain an acceptable quality of life for a long time. This applies to patients in the CK D category who received complete replacement therapy. It is noted that previously the average life expectancy of such patients was around 40-50 years, but now this indicator has been extended to 20 years. At the same time, a significant part of dialysis patients are women of climacteric age. Some of them are in the climacteric period, and various somatic and mental changes are observed.

According to scientific studies, replacement therapy-hemodialysis itself leads to a decrease in the quality of life in women with this syndrome. It is precisely the changes that occur in this type of patient, since they are not fully studied, that form the basis of our scientific research.


Амбрамова Е.Э., Королева И.Е., Тов Н.Л. и др. Факторы риска летальных исходов у больных на гемодиализе // Journal of Siberian Medical Sciences 2015, №6, С. 15-26.

Мирзаева Барно Миркамол кизи. Ренальная остеодистрофия у больныхтерминальной стадии почечной недостаточности, получающих гемодиализ, и пути её коррекции. Диссертация. 2020г.

Мунавваров Б.А., Сурункали буйрак касаллиги билан огриган беморларда гипоазотемик дори-воситаларини куллаш билан даволашни мукобиллаштириш. Автореферат. 2020й.

Профессор Зайдиева Я.З.Альтернативная терапия менопаузальных расстройств у женщин в климактерии. Акушерство/Гинекология. РМЖ, 2017 № 12. С. 873-878.

Сметник В.П. Менопаузальная гормонотерапия и сохранение здоровьяженщин зрелого возраста. Клинические рекомендации: протоколы // Климактерий. 2015. 49 cтр.

Султонов Н.Н., Сурункали буйрак касаллиги билан огриган беморларда гемодинамик бузилишларни бахолашда антиагрегант терапияни мукобиллаштириш. 2020й.

Шарапов О.Н., Сердечно-сосудистые заболевания у больных получающих гемодиализ. 2021г.

Хроническая болезнь почек (ХБП) клинические рекомендации. 2021г. 3-й


Baber R.J., Panay N., Fenton A. et al. IMS Recommendations on women’s midlife health and menopause hormone therapy (MHT) // Climacteric. 2016. Vol. 19(2). P. 109–150.

Bobokulov M. B., Sabirov M. A., Munavvarov B.A., Evaluation of the Morphofunctional State of the Transplant in the Period after Kidney Transplantation NeuroQuantology - All Rights Reserved. Volume 20, No 8 (2022) P.9877-9884. DOI: 10.48047/nq.2022.20.8.NQ221009.

Daminova K.M., Sabirov M.A., Babajanova N.R., Daminova H.M., Munavvarov B.A., Some Risk Factors For The Development And Progression Of Chronic Kidney Disease In A Primary Line Of Health Care. Chin J Ind Hyg Occup Dis, 2021,Vol.39,No.7.

Guidelines for hormone treatment of women in the menopausal transition and beyond / F. Naftolin, H.P. Schneider, I.D. Sturdee et al. // Position state-ment by the Executive Committee of the International Menopause Society. – 2015. – 127 (3–4). – P. 94–96.

Hruska K.A., Mathew S., Lund R. et al. Hyperphosphatemia of chronic kidney disease // Kidney International. 2018. №74. Р. 148–157.

Sultonov, N. N., Sabirov, M. O., Tashpulatova, M. H., & Maksudova, L. I. (2020). Evaluating the effectiveness of antiplatelet therapy of the patients with kidney disease. European Journal of Molecular and Clinical Medicine, 7(8), 1500-1505.